
S2 Episode 1: Breaking Bladder Cancer Barriers: The Promise of Gene Therapy
Failed to add items
Add to Cart failed.
Add to Wish List failed.
Remove from wishlist failed.
Adding to library failed
Follow podcast failed
Unfollow podcast failed
-
Narrated by:
-
By:
About this listen
Drs Cheryl Lee and Stephen Boorjian share detailed insights about a model drug development partnership involving the first-in-class therapy for BCG-unresponsive non–muscle-invasive bladder cancer.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/987104). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Diagnosis and Treatment of Non-muscle Invasive Bladder Cancer: AUA/SUO Guideline (2020) https://www.auanet.org/guidelines-and-quality/guidelines/bladder-cancer-non-muscle-invasive-guideline
ADSTILADRIN (=INSTILADRIN) in Patients With High Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC) https://clinicaltrials.gov/ct2/show/NCT02773849
Intravesical Nadofaragene Firadenovec Gene Therapy for BCG-unresponsive Non-muscle-invasive Bladder Cancer: A Single-arm, Open-label, Repeat-dose Clinical Trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7988888/